NLRP3 and COVID-19: The ability of colchicine to reduce the length of stay in hospitalized patients with COVID‐19 is consistent with its potential to prevent cytokine storm via inhibition of NLRP3 inflammasome, which could prevent clinical deterioration of colchicine users with COVID‐19.